Life AI Net
Inicio
Archivo
Calculadoras
Directorio
Boletín
Hot
Iniciar sesión
Español
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
Inicio
Archivo
Calculadoras
Directorio
Boletín
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
Iniciar sesión
Inicio
Archivo
Calculadoras
Directorio
More
En vivo
FierceBiotech
Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target
FierceBiotech
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
FierceBiotech
Ray Therapeutics shines a light on $125M round targeting genetic eye therapy
FierceBiotech
Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia
FierceBiotech
Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
Lonza News
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Perf - GuruFocus
Lonza News
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks fo - PharmiWeb.com
Lonza News
Simulations Plus partners with Lonza and FDA on drug formulation research - Investing.com
BioWorld
Japanese researchers report new μ-opioid receptor antagonists
BioWorld
Incyte discloses new TYK2 and/or JAK1 inhibitors
BioWorld
Insilico Medicine divulges new NLRP3 inflammasome inhibitors
BioWorld
Neolaia synthesizes new CD38 inhibitors
FierceBiotech
Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target
FierceBiotech
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
FierceBiotech
Ray Therapeutics shines a light on $125M round targeting genetic eye therapy
FierceBiotech
Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia
FierceBiotech
Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
Lonza News
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Perf - GuruFocus
Lonza News
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks fo - PharmiWeb.com
Lonza News
Simulations Plus partners with Lonza and FDA on drug formulation research - Investing.com
BioWorld
Japanese researchers report new μ-opioid receptor antagonists
BioWorld
Incyte discloses new TYK2 and/or JAK1 inhibitors
BioWorld
Insilico Medicine divulges new NLRP3 inflammasome inhibitors
BioWorld
Neolaia synthesizes new CD38 inhibitors
Archivo
Buscar
Buscar
Reciente
Más antiguo
Borrar
@BioWorld
Total
1057
Fuente
BioWorld
Búsqueda
--
BioWorld
23 mar 2026
In the clinic for March 23, 2026
BioWorld
23 mar 2026
Other news to note for March 23, 2026
BioWorld
23 mar 2026
Regulatory actions for March 23, 2026
BioWorld
23 mar 2026
Biggest gainers and losers for March 16-20, 2026
BioWorld
23 mar 2026
Daiichi Sankyo patents SF-1 degradation inducers
BioWorld
23 mar 2026
BTK inhibitors disclosed in Ewha Womans University patent
BioWorld
23 mar 2026
Abbisko synthesizes new GTPase KRAS mutant inhibitors
BioWorld
20 mar 2026
Biopharma money raised: Jan. 1-March 20, 2026
BioWorld
20 mar 2026
Money raised by biopharma
BioWorld
20 mar 2026
Other news to note for March 20, 2026
BioWorld
20 mar 2026
Regulatory actions for March 20, 2026
BioWorld
20 mar 2026
After judge’s injunction, will ACIP disband?
BioWorld
20 mar 2026
Synnovation’s PI3Kα inhibitor portfolio draws Novartis in $3B deal
BioWorld
20 mar 2026
FDA, NIH mark milestones toward reducing animal testing
BioWorld
20 mar 2026
Treeline Biosciences reports TEAD degraders
BioWorld
20 mar 2026
Muscarinic M4 receptor PAMs disclosed in Suven Life Sciences patent
BioWorld
20 mar 2026
Omass Therapeutics identifies melanocortin MC2 receptor antagonists
BioWorld
20 mar 2026
ADPD 2026: Three inflection points to target Alzheimer’s disease
Anterior
12 / 59
Siguiente